Pages that link to "Q38457772"

The following pages link to Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status (Q38457772):

Displaying 49 items.

• Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2 (Q21134904) (← links)
• Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry (Q24797806) (← links)
• HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity (Q27006811) (← links)
• Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event (Q28245213) (← links)
• MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions (Q33273821) (← links)
• Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients (Q33390513) (← links)
• Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas (Q34371749) (← links)
• Testing for HER2 in Breast Cancer: A Continuing Evolution (Q34424285) (← links)
• HER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors (Q35323892) (← links)
• The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas (Q35687706) (← links)
• Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma (Q36616556) (← links)
• Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements (Q37000037) (← links)
• The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies (Q37326072) (← links)
• Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response (Q37406389) (← links)
• Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). (Q38347216) (← links)
• Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. (Q38414983) (← links)
• HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma (Q38450375) (← links)
• Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays (Q38452406) (← links)
• Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens (Q38612634) (← links)
• Potential Biomarkers in Diagnosis of Human Gastric Cancer (Q38757877) (← links)
• MicroRNA-21 Expression in Primary Breast Cancer Tissue Among Egyptian Female Patients and its Correlation with Chromosome 17 Aneusomy (Q38854683) (← links)
• Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients. (Q40135743) (← links)
• Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status (Q41133771) (← links)
• Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification (Q41821797) (← links)
• Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification (Q41955766) (← links)
• Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification (Q42718689) (← links)
• Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer (Q43843193) (← links)
• Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. (Q43963074) (← links)
• A comparison of five immunohistochemical biomarkers and HER‐2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early‐onset breast carcinoma (Q44611360) (← links)
• Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). (Q45967763) (← links)
• Folate deficiency in human peripheral blood lymphocytes induces chromosome 8 aneuploidy but this effect is not modified by riboflavin. (Q45994967) (← links)
• Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome (Q47231231) (← links)
• Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma (Q51056791) (← links)
• Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas (Q51510677) (← links)
• Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. (Q52976761) (← links)
• Evaluation of Genetic Status of HER-2/neu and Aneusomy 17 by Fluorescence In Situ Hybridization and Comparison with Immunohistochemistry Assay from Indian Breast Cancer Patients (Q53210917) (← links)
• Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes. (Q53581875) (← links)
• Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. (Q54256014) (← links)
• Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer. (Q54313117) (← links)
• Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. (Q54318735) (← links)
• No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. (Q54536990) (← links)
• Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer (Q54581383) (← links)
• The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study (Q54635889) (← links)
• Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. (Q54687747) (← links)
• Marginal zone and mantle cell lymphomas: assessment of cytomorphology in subtyping small B-cell lymphomas (Q73083573) (← links)
• Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals (Q80788489) (← links)
• HER-2, TOP2A and chromosome 17 alterations in breast cancer (Q81408242) (← links)
• EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast (Q83147969) (← links)
• Breast Cancer With a HER2 IHC2 and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event (Q97423486) (← links)